These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance. Ravichandra A; Bhattacharjee S; Affò S Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700 [TBL] [Abstract][Full Text] [Related]
4. Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma. Zhong YJ; Luo XM; Liu F; He ZQ; Yang SQ; Ma WJ; Wang JK; Dai YS; Zou RQ; Hu YF; Lv TR; Li FY; Hu HJ J Transl Med; 2024 May; 22(1):422. PubMed ID: 38702814 [TBL] [Abstract][Full Text] [Related]
6. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870 [TBL] [Abstract][Full Text] [Related]
7. Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma. Sha M; Jeong S; Qiu BJ; Tong Y; Xia L; Xu N; Zhang JJ; Xia Q Cancer Med; 2018 Sep; 7(9):4665-4677. PubMed ID: 30062820 [TBL] [Abstract][Full Text] [Related]
11. Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma. Ying F; Chan MSM; Lee TKW Cell Mol Gastroenterol Hepatol; 2023; 15(4):985-999. PubMed ID: 36708970 [TBL] [Abstract][Full Text] [Related]
12. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. Dzobo K; Dandara C OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970 [TBL] [Abstract][Full Text] [Related]
13. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma. Zhang Y; Yan HJ; Wu J Curr Cancer Drug Targets; 2024; 24(7):681-700. PubMed ID: 38213139 [TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of Cholangiocarcinoma Immune Biology. Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C Cells; 2023 Mar; 12(6):. PubMed ID: 36980187 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128 [TBL] [Abstract][Full Text] [Related]
18. Modulating PCGF4/BMI1 Stability Is an Efficient Metastasis-Regulatory Strategy Used by Distinct Subtypes of Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma. Hu J; Xu H; Ma X; Bai M; Zhou Y; Miao R; Wang F; Li X; Cheng B Am J Pathol; 2024 Jul; 194(7):1388-1404. PubMed ID: 38670529 [TBL] [Abstract][Full Text] [Related]
19. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Wang J; Ilyas S Expert Opin Investig Drugs; 2021 Apr; 30(4):429-438. PubMed ID: 33322977 [No Abstract] [Full Text] [Related]
20. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma. Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918 [No Abstract] [Full Text] [Related] [Next] [New Search]